Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21

Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21Supplementary Table 21 is the source data for figure 5 Supplementary Table legends: Supplementary Table 1. Distribution of samples with varying molecular characterization available for analysis.Supplementary Table 2. Association between genomic context, tumor type, grade with A) 5-hmC MDI and B) 5-mC MDI, determined by linear regression.Supplementary Table 3. Association between tumor purity, grade with A) 5-hmC MDI and B) 5-mC MDI, determined by linear regression.Supplementary Table 9. A) Annotation of gene name and genomic context of 28 dhmCpGs shared across tumor types. B) Proportion of shared dhmCpGs relative to CpG islands. C) Proportion of shared dhmCpGs in different genomic contexts.Supplementary Table 14. The number of differentially expressed genes with differentially hydroxymethylated CpGs identified by bulk tissue epigenome-wide association study. Categorized by the direction of gene expression change and the genomic context of the differentially hydroxymethylated CpGs for each tumor type.Supplementary Table 15. The number of nuclei from single nuclei RNA-seq that were included in the CellDMC analysis.Supplementary Table 16. The number of differentially hydroxymethylated CpGs per tumor type identified by CellDMC. Categorized by the change in the level of hydroxymethylation and cell type of association.Supplementary Table 21. Cell type-driven dhmCpGs and dmCpGs enrichment at genomic contexts.